PEG-MGF

—

evidence score

peptide

Research Only

Evidence Level D

pegylated mechano growth factorPEGylated IGF-1Ec

PEG-MGF refers to pegylated variants of mechano growth factor (an IGF-1 splice-related peptide) marketed in performance circles for injury recovery and local hypertrophy. Most evidence is preclinical, and commercial products often lack batch-level analytical verification.

Safety & legal caution

Educational database only — not medical or legal advice.

Safety

Human efficacy and safety evidence is sparse and low quality.
Unknown long-term carcinogenic and fibrotic risk profile.
Significant peptide identity/purity uncertainty outside validated labs.

Legal / compliance

Research-only status in most regions; typically not legal for medical marketing.
Likely anti-doping prohibited as a growth factor analog.

Current literature links

Local expression of IGF-1 isoforms in muscle damage and repair(2003)Growth factors and performance enhancement governance(2025)

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

Preclinical

Last Sync

Not synced yet

Last Reviewed

Not reviewed yet

Dosing

Typical

200 mcg

100 mcgRange400 mcg

Frequency2–4x/week in non-clinical protocols

Set height & weight in Settings to see your dose.

Pharmacology

Half-lifeVariable; pegylation extends native MGF persistence

OnsetUnknown in humans

DurationLikely multi-hour to day-scale depending on construct

Routes

subcutaneous

intramuscular

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(24%)—

Quality(24%)—

Sample Size(12%)—

Consistency(14%)—

Replication(8%)—

Recency(18%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

PEG-MGF is currently categorized as a peptide compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Experimental IGF-axis splice-variant signaling intended to influence muscle repair pathways

Practical Context

Strongest current signals

No indexed study summaries yet.